Clinical studies for a therapy for Duchenne muscular dystrophy have begun at Sirius University and the Russian biotech business Generium. At a gathering at...
Cumberland Pharmaceuticals, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase...
ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA)...
Several research groups have been attempting to create compact CRISPR systems that can fit into a single AAV vector while maintaining editing capabilities. The...